Lineage Cell Therapeutics Announces 2024 Annual Meeting of Shareholders on June 11
Ticker: LCTX · Form: DEF 14A · Filed: Apr 29, 2024 · CIK: 876343
| Field | Detail |
|---|---|
| Company | Lineage Cell Therapeutics, Inc. (LCTX) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 19 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: Proxy Statement, Annual Meeting, Shareholder Vote, Director Election, Executive Compensation
TL;DR
<b>Lineage Cell Therapeutics will hold its 2024 Annual Meeting of Shareholders on June 11, 2024, to elect directors, ratify auditors, and vote on executive compensation.</b>
AI Summary
Lineage Cell Therapeutics, Inc. (LCTX) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Annual meeting scheduled for June 11, 2024, at 8:00 a.m. Pacific Time in Carlsbad, CA. Shareholders will vote on electing eight directors for the 2025 annual meeting. The appointment of WithumSmith+Brown, PC as independent registered public accounting firm for FY2024 will be ratified. Shareholders will provide advisory approval for named executive officer compensation. April 19, 2024, is the record date for determining shareholders eligible to vote.
Why It Matters
For investors and stakeholders tracking Lineage Cell Therapeutics, Inc., this filing contains several important signals. The election of directors and ratification of auditors are standard corporate governance procedures crucial for company oversight and financial integrity. Shareholder advisory votes on executive compensation provide direct feedback on the company's pay practices and alignment with performance.
Risk Assessment
Risk Level: low — Lineage Cell Therapeutics, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual shareholder meeting, with no immediate financial or operational changes indicated.
Analyst Insight
Shareholders should review the director nominees and executive compensation proposals before the June 11, 2024 meeting.
Key Numbers
- 8 — Directors to be elected (To hold office until the 2025 annual meeting.)
- 2024 — Fiscal Year End (For which WithumSmith+Brown, PC is proposed as auditor.)
Key Players & Entities
- Lineage Cell Therapeutics, Inc. (company) — Registrant and filer of the proxy statement.
- WithumSmith+Brown, PC (company) — Proposed independent registered public accounting firm.
- June 11, 2024 (date) — Date of the annual meeting of shareholders.
- April 19, 2024 (date) — Record date for determining shareholders entitled to vote.
- 2025 (date) — Year until which elected directors will hold office.
- December 31, 2024 (date) — Fiscal year end for which auditors are appointed.
FAQ
When did Lineage Cell Therapeutics, Inc. file this DEF 14A?
Lineage Cell Therapeutics, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 29, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Lineage Cell Therapeutics, Inc. (LCTX).
Where can I read the original DEF 14A filing from Lineage Cell Therapeutics, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Lineage Cell Therapeutics, Inc..
What are the key takeaways from Lineage Cell Therapeutics, Inc.'s DEF 14A?
Lineage Cell Therapeutics, Inc. filed this DEF 14A on April 29, 2024. Key takeaways: Annual meeting scheduled for June 11, 2024, at 8:00 a.m. Pacific Time in Carlsbad, CA.. Shareholders will vote on electing eight directors for the 2025 annual meeting.. The appointment of WithumSmith+Brown, PC as independent registered public accounting firm for FY2024 will be ratified..
Is Lineage Cell Therapeutics, Inc. a risky investment based on this filing?
Based on this DEF 14A, Lineage Cell Therapeutics, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual shareholder meeting, with no immediate financial or operational changes indicated.
What should investors do after reading Lineage Cell Therapeutics, Inc.'s DEF 14A?
Shareholders should review the director nominees and executive compensation proposals before the June 11, 2024 meeting. The overall sentiment from this filing is neutral.
How does Lineage Cell Therapeutics, Inc. compare to its industry peers?
Lineage Cell Therapeutics operates in the biotechnology sector, focusing on cell therapeutics. Annual meetings are standard for publicly traded companies to address governance and shareholder interests.
Are there regulatory concerns for Lineage Cell Therapeutics, Inc.?
The filing is made under Schedule 14A of the Securities Exchange Act of 1934, governing proxy solicitations.
Risk Factors
- Compliance with SEC Regulations [low — regulatory]: The company must comply with all SEC rules and regulations regarding proxy solicitations and shareholder meetings.
- Effectiveness of Board of Directors [low — operational]: The election of qualified and effective directors is crucial for the company's strategic direction and oversight.
- Auditor Independence and Effectiveness [low — financial]: Ratification of the independent auditor ensures the integrity of financial reporting.
Industry Context
Lineage Cell Therapeutics operates in the biotechnology sector, focusing on cell therapeutics. Annual meetings are standard for publicly traded companies to address governance and shareholder interests.
Regulatory Implications
The filing is made under Schedule 14A of the Securities Exchange Act of 1934, governing proxy solicitations.
What Investors Should Do
- Review the biographies and qualifications of the director nominees.
- Understand the company's rationale for executive compensation proposals.
- Vote your shares by the deadline to ensure your voice is heard on these important matters.
Key Dates
- 2024-06-11: Annual Meeting of Shareholders — Shareholders will vote on key corporate matters.
- 2024-04-19: Record Date — Determines shareholders eligible to vote at the meeting.
- 2024-04-29: Filing Date — Date the Definitive Proxy Statement was filed with the SEC.
Year-Over-Year Comparison
This is a routine DEF 14A filing for the annual shareholder meeting, similar to previous years, outlining standard agenda items.
Filing Stats: 4,792 words · 19 min read · ~16 pages · Grade level 10.3 · Accepted 2024-04-29 16:30:13
Filing Documents
- lctx_proxy_2024.htm (DEF 14A) — 869KB
- img30298293_0.jpg (GRAPHIC) — 5KB
- img30298293_1.jpg (GRAPHIC) — 193KB
- img30298293_2.jpg (GRAPHIC) — 141KB
- img30298293_3.jpg (GRAPHIC) — 1337KB
- img30298293_4.jpg (GRAPHIC) — 162KB
- 0000950170-24-049935.txt ( ) — 3400KB
From the Filing
DEF 14A 1 lctx_proxy_2024.htm DEF 14A DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 Lineage Cell Therapeutics, Inc. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 2173 Salk Ave., Suite 200 Carlsbad, CA 92008 (442) 287-8990 www.lineagecell.com NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To Be Held June 11, 2024 To the Shareholders of Lineage Cell Therapeutics, Inc.: The 2024 annual meeting of shareholders (the “ Meeting ”) of Lineage Cell Therapeutics, Inc. (“ Lineage ,” “ we ,” “ us ,” and “ our ”) will be held at 2173 Salk Avenue, Suite 200, Carlsbad, CA 92008 on June 11, 2024 at 8:00 a.m. Pacific Time for the following purposes: 1. To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified. 2. To ratify the appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for our fiscal year ending December 31, 2024. 3. To approve, on an advisory basis, the compensation paid to our named executive officers. 4. To transact such other business as may properly come before the Meeting or any adjournment or postponement thereof. The foregoing items of business are more fully described in the accompanying Proxy Statement, which forms a part of this notice and is incorporated herein by reference. All shareholders are cordially invited to attend the Meeting. Our board of directors has fixed the close of business on April 19, 2024 as the record date for determining shareholders entitled to receive notice of, and to vote at, the Meeting or any adjournment or postponement thereof. Your vote is important. Whether or not you expect to attend the Meeting, please vote as soon as possible. You may authorize a proxy to vote your shares via the Internet, by telephone, or—if you have received and/or requested paper copies of our proxy materials by mail—by signing, dating and returning the proxy card in the envelope provided. For specific voting instructions, please refer to the information provided in the accompanying Proxy Statement and in the Notice of Internet Availability of Proxy Materials. By Order of the Board of Directors, /s/ Brian M. Culley Brian M. Culley Chief Executive Officer and Director Carlsbad, California April 29, 2024 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 11, 2024 The board of directors (“ Board ”) of Lineage Cell Therapeutics, Inc. (“ Lineage ,” “ we ,” “ us ” and “ our ”) is soliciting proxies for use at our 2024 annual meeting of shareholders (the “ Meeting ”) to be held at 2173 Salk Avenue, Suite 200, Carlsbad, CA 92008 on June 11, 2024 at 8:00 a.m. Pacific Time, including any adjournment or postponement thereof. Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Shareholders to be Held on June 11, 2024: This Proxy Statement and our 2023 Annual Report are available at www.proxydocs.com/LCTX . QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS AND THE ANNUAL MEETING Why am I receiving these materials? We have prepared these proxy materials, including this Proxy Statement and the related proxy card, because our Board is soliciting your proxy to vote at the Meeting. This Proxy Statement summarizes information related to your vote at the Meeting. All shareholders of record at the close of business on April 19, 2024, the record date for the Meeting, and those who hold a valid proxy on their behalf, are cordially invited to attend the Meeting in person. However, you do not need to attend the Meeting to vote your shares. Instead, you may simply submit your proxy in accordance with the instructions provided on the Notice of Internet Availability of Proxy Materials, or if you elected to receive printed copies of the proxy materials, you may submit your proxy by completing, signing and returning the enclosed proxy card. See also, “How do I vote?” below. The proxy materials were first sent or made available to our sharehol